Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Honda Motor Company Ltd. Common Stock (HMC) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Honda Motor Company Ltd. Common StockTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Honda Motor Company Ltd. Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Honda Motor Company Ltd. Common Stock trades at $32.74 (market cap $42.17B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M). The key difference: Honda Motor Company Ltd. Common Stock is far larger — about 375.9× Inovio Pharmaceuticals Inc's market cap, and Honda Motor Company Ltd. Common Stock pays a 4.1% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honda Motor Company Ltd. Common Stock for 1 Days and Inovio Pharmaceuticals Inc for 43 Days on average.

HMCINO
Market Cap
$42.17B$112.19M
Volume
1,251,3083,201,278
Sector
Consumer CyclicalHealth
52-Week High
$33.37$2.65
52-Week Low
$23.49$0.66
Typical Hold Time
1 Days43 Days
Enterprise Value
$39.34B$83.51M
Dividend Yield
4.1%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Honda Motor Company Ltd. Common Stock

No Aura AI signal available yet.

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.

The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HMC

No sentiment data available yet.

INO
96% Buy4% Sell
Avg holding period · 43 Days

About Honda Motor Company Ltd. Common Stock

Honda Motor manufactures automobiles, motorcycles, power products, and related financial services. Its brands serve consumer and commercial transportation markets globally.

Read more on HMC →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →